Patients’ Right to Know Their Medication Act of 2025

Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocating for the Patients Right to Know Their Medication Act (HR 5133), which requires the information to be provided in printed form. Opposing the Pharmaceutical Information Modernization Act of 2025 (H.R. 4132/S. 2027), which would allow the FDA to finalize a proposed rule permitting drug manufacturers to send prescribing information electronically, instead of on printed paper.

Client expense: $50,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act; H.R. 4409, the Fair Pharmacies for Federal Employees Act; S.3549/H.R.6837, the Fiduciary Accountability, Integrity and Reform (FAIR) Act; H.R.7148, the Consolidated Appropriations Act of 2026; Rural Health Transformation Program; Creation and Implementation of TrumpRx; Comments to FDA on RFI, "Re: Increasing Access to Nonprescription Drugs; Request for Information"; S.3822, Break up Big Medicine Act; Comments to FDA on RFT, "Re: [Docket No. FDA-2025-N-6743] - Scientific and Clinical Considerations for Testosterone Replacement Therapy (TRT) in Men with Hypogonadism"; Comments to DoL, HHS, and DoT regarding "Re: Transparency in Coverage Proposed Rule [CMS-9882-P]"; Pharmacy Shortage Areas in reference to USC-NCPA joint project Mapping Tool; H.R. 7895, the PBM Kickback Prohibition Act; Comments to FDA on their comment request "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Medication Guides for Prescription Drug Products [FDA-2025-N-6869]";

Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.1874/H.R.3593 - Title VIII Nursing Workforce Reauthorization Act of 2025 S.3435/H.R.6607 - Future Advancement of Academic Nursing (FAAN) Act S.3707/H.R.7279 - Nurse Faculty Shortage Reduction Act of 2026 S.3296/H.R.3170 - Improving Access to Workers Compensation for Injured Federal Workers Act S.1599/H.R.6394 - Midwives for Maximizing Optimal Maternity Service (MOMS) Act S.2954 - Health Care Workforce Expansion Act H.R.7973 - Momnibus Act H.R.3333 - Magnifying Opportunities to Recruit and Educate (MORE) Nurses Act H.R.1 - One Big Beautiful Bill Act [Public Law No. 119-21] H.R.5133 - Patients Right to Know Their Medication Act Support for health care programs Rural health and Rural Health Transformation Program Nursing education, workforce, research, and public health needs Support for clinical education Support for the National Institutes of Health, the National Institute of Nursing Research, nurse scientists and researchers, and national biomedical research Issues surrounding federal agency restructuring Issues surrounding public health nursing Addressing health care nursing workforce shortage and supporting nursing education pathways, clinical education, and academic progression Reduce regulatory barriers within federal programs so APRNs can practice to the full extent of their education and clinical training Proposed changes to the U.S. childhood vaccine schedule Cancellations of federal nursing grants

Client expense: $80,000 · Firm income: Not reported

Advocating for the Patients Right to Know Their Medication Act (HR 5133), which requires the information to be provided in printed form. Opposing the Pharmaceutical Information Modernization Act of 2025 (H.R. 4132/S. 2027), which would allow the FDA to finalize a proposed rule permitting drug manufacturers to send prescribing information electronically, instead of on printed paper.

Client expense: $50,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting"; H.R.5316, the Drug Shortage Compounding and Patient Access Act; H.R.5256, the 340B ACCESS Act; Comments to FDA on "RE: Docket No. FDA-2025-N-2589, Comments on the Risks and Benefits of Menopause Hormone Therapy"; H.Res. 805, Recognizing October 2025 as American Pharmacists Month in honor of the contribution of pharmacists to provide safe, accessible, affordable, and beneficial patient care services and products to all residents and protect the public health of our communities; S.3345, the PBM Price Transparency and Accountability Act; H.R. 6609, Pharmacists Fight Back in Medicare and Medicaid Act; H.R. 6610, Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]; H.R. 6703, the Lower Health Care Premiums for All Americans Act; H.R.5133, the Patient's Right to Know Their Medication Act;

In favor of sustainable printed pharmaceutical literature and H.R. 5133 the Patients' Right to Know Their Medication Act.

Client expense: $7,200 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE